Colon Cancer Screening, Healthy Person
Conditions
Keywords
progastrin, screening, bio-marker, healthy person, early stage
Brief summary
Dosage of progastrin in asymptomatic person participating in colon cancer screening
Detailed description
For anyone who will participate in colon screening at the Princess Grace Hospital of Monaco and who has signed the informed consent document. A blood test will be performed in addition to the screening test to assess the rate of progastrin.
Interventions
DIAGNOSTIC_TESTprogastrin
PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
Sponsors
Centre Hospitalier Princesse Grace
ECS-Progastrin SA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Interventional Research, at Risk and Minimal Constraints, Category 2
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* participant in colon cancer screening * signing informed consent
Exclusion criteria
* any major medical, psychiatric or addictive illness that would affect the informed consent process * The consent of a representative is not allowed in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progastrin rate | from 15 days to 2 months (until results are obtained) | measuring the rate of progastrin in the blood |
Countries
France
Outcome results
None listed